BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 29782361)

  • 1. The Significance of Para-Aortic Nodal Size and the Role of Adjuvant Systemic Chemotherapy in Cervical Cancer: An Institutional Experience.
    Manders DB; Sims TT; Bailey A; Hwang L; Richardson DL; Miller DS; Kehoe SM; Albuquerque KV; Lea JS
    Am J Clin Oncol; 2018 Dec; 41(12):1225-1230. PubMed ID: 29782361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended field radiotherapy with or without chemotherapy in patients with cervical cancer and positive para-aortic lymph nodes: a single institution retrospective review.
    Ng BH; Rozita A; Adlinda A; Lee WC; Wan Zamaniah W
    Asian Pac J Cancer Prev; 2015; 16(9):3827-33. PubMed ID: 25987044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of salvage therapies for isolated para-aortic lymph node recurrence in patients with uterine cervical cancer after definitive treatment.
    Kubota H; Tsujino K; Sulaiman NS; Sekii S; Matsumoto Y; Ota Y; Soejima T; Yamaguchi S; Sasaki R
    Radiat Oncol; 2019 Dec; 14(1):236. PubMed ID: 31878944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose, prophylactic, extended-field, intensity-modulated radiotherapy plus concurrent weekly cisplatin for patients with stage IB2-IIIB cervical cancer, positive pelvic lymph nodes, and negative para-aortic lymph nodes.
    Liang JA; Chen SW; Hung YC; Yeh LS; Chang WC; Lin WC; Chang YY
    Int J Gynecol Cancer; 2014 Jun; 24(5):901-7. PubMed ID: 23975081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns of Recurrence in Node-Positive Cervical Cancer Patients Treated With Contemporary Chemoradiation and Dose Escalation: A Multi-Institutional Study.
    Sethi R; Mayadev J; Sethi S; Rash D; Chen LM; Brooks R; Ueda S; Hsu IC
    Pract Radiat Oncol; 2019 Mar; 9(2):e180-e186. PubMed ID: 30342181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment outcomes of extended-field radiation therapy and the effect of concurrent chemotherapy on uterine cervical cancer with para-aortic lymph node metastasis.
    Yoon HI; Cha J; Keum KC; Lee HY; Nam EJ; Kim SW; Kim S; Kim YT; Kim GE; Kim YB
    Radiat Oncol; 2015 Jan; 10():18. PubMed ID: 25582425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended field chemoradiation for cervical cancer patients with histologically proven para-aortic lymph node metastases after laparaoscopic lymphadenectomy.
    Marnitz S; Schram J; Budach V; Sackerer I; Vercellino GF; Sehouli J; Köhler C
    Strahlenther Onkol; 2015 May; 191(5):421-8. PubMed ID: 25413986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Added value of para-aortic surgical staging compared to
    De Cuypere M; Lovinfosse P; Goffin F; Gennigens C; Rovira R; Duch J; Fastrez M; Gebhart G; Squifflet JL; Luyckx M; Charaf G; Crener K; Buxant F; Bucella D; Jouret M; Hustinx R; Kridelka F
    Eur J Surg Oncol; 2020 May; 46(5):883-887. PubMed ID: 31784203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant carboplatin and paclitaxel after concurrent cisplatin and radiotherapy in patients with locally advanced cervical cancer.
    Yavas G; Yavas C; Sen E; Oner I; Celik C; Ata O
    Int J Gynecol Cancer; 2019 Jan; 29(1):42-47. PubMed ID: 30640682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors associated with radiotherapy for cervical cancer with computed tomography-detected para-aortic lymph node metastasis.
    Wu SY; Huang EY; Chanchien CC; Lin H; Wang CJ; Sun LM; Chen HC; Fang FM; Hsu HC; Huang YJ
    J Radiat Res; 2014 Jan; 55(1):129-38. PubMed ID: 23814113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended-field intensity-modulated radiation therapy combined with concurrent chemotherapy for cervical cancer with para-aortic lymph nodes metastasis.
    Liu X; Wang W; Meng Q; Zhang F; Hu K
    Jpn J Clin Oncol; 2019 Mar; 49(3):263-269. PubMed ID: 30668725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicity and early clinical outcomes in cervical cancer following extended field helical tomotherapy to para-aortic lymph nodes.
    Jouglar E; Thomas L; de la Rochefordière A; Noël G; Le Blanc-Onfroy M; Delpon G; Campion L; Mahé MA
    Cancer Radiother; 2016 Dec; 20(8):794-800. PubMed ID: 28270323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoradiation and the Role of Adjuvant Chemotherapy in Lymph Nodal-Metastatic Cervical Cancer.
    Ali N; Valimohammad AT; Abbasi AN; Mansha MA; Hafiz A; Qureshi BM
    J Glob Oncol; 2018 Sep; 4():1-4. PubMed ID: 30241186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended-field intensity-modulated radiotherapy and concurrent cisplatin-based chemotherapy for postoperative cervical cancer with common iliac or para-aortic lymph node metastases: a retrospective review in a single institution.
    Zhang G; Fu C; Zhang Y; Wang J; Qiao N; Yang Q; Cheng Y
    Int J Gynecol Cancer; 2012 Sep; 22(7):1220-5. PubMed ID: 22854654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maximum Standardized Uptake Value of Pelvic Lymph Nodes in [18F]-Fluorodeoxyglucose Positron Emission Tomography Is a Prognostic Factor for Para-Aortic Lymph Node Recurrence in Pelvic Node-Positive Cervical Cancer Treated With Definitive Chemoradiotherapy.
    Kim DH; Kim WT; Bae JS; Ki YK; Park D; Suh DS; Kim KH; Lee JH; Lee JY; Jeon HS; Nam JH
    Int J Gynecol Cancer; 2016 Sep; 26(7):1274-80. PubMed ID: 27465890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cervical cancer with paraaortic involvement: do patients truly benefit from tailored chemoradiation therapy? A retrospective study on 8 French centers.
    Chantalat E; Vidal F; Leguevaque P; Lepage B; Mathevet P; Deslandres M; Motton S
    Eur J Obstet Gynecol Reprod Biol; 2015 Oct; 193():118-22. PubMed ID: 26295788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathological Risk Factors and Outcomes in Women With Stage IB2 Cervical Cancer Treated With Primary Radical Surgery Versus Chemoradiotherapy.
    Bradbury M; Founta C; Taylor W; Kucukmetin A; Naik R; Ang C
    Int J Gynecol Cancer; 2015 Oct; 25(8):1476-83. PubMed ID: 26244756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant therapy after radical surgery for stage IB-IIB cervical adenocarcinoma with risk factors.
    Seki T; Tanabe H; Nagata C; Suzuki J; Suzuki K; Takano H; Isonishi S; Ochiai K; Takakura S; Okamoto A
    Jpn J Clin Oncol; 2017 Jan; 47(1):32-38. PubMed ID: 27677664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of patients with incomplete resection after surgery for stage IB2/II cervical carcinoma with chemoradiation therapy.
    Uzan C; Vincens E; Balleyguier C; Gouy S; Pautier P; Duvillard P; Haie-Meder C; Morice P
    Int J Gynecol Cancer; 2010 Apr; 20(3):379-84. PubMed ID: 20375801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is there a role for postoperative treatment in patients with stage Ib2-IIb cervical cancer treated with neo-adjuvant chemotherapy and radical surgery? An Italian multicenter retrospective study.
    Landoni F; Sartori E; Maggino T; Zola P; Zanagnolo V; Cosio S; Ferrari F; Piovano E; Gadducci A
    Gynecol Oncol; 2014 Mar; 132(3):611-7. PubMed ID: 24342439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.